Treatment of mature B-ALL and high grade B-NHL in children

Best Practice and Research: Clinical Haematology

Volumn 15, Issue 4, 2002, Pages 695-711

  Patte, Catherine ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

B cell lymphoma; Burkitt; Central nervous system prophylaxis; Children; L3ALL; Polychemotherapy; Tumour lysis syndrome

Indexed keywords

ALKYLATING AGENT; ALLOPURINOL; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BUSULFAN; CARMUSTINE; CD20 ANTIGEN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; FOLINATE CALCIUM; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROCORTISONE; IFOSFAMIDE; IMMUNOGLOBULIN; MELPHALAN; METHOTREXATE; MONOCLONAL ANTIBODY; MYC PROTEIN; PREDNISOLONE; RITUXIMAB; UNINDEXED DRUG; URATE OXIDASE; VINCRISTINE; EPIPODOPHYLLOTOXIN; PREDNISONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADAPTATION; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURGERY; CELL MATURATION; CENTRAL NERVOUS SYSTEM; CHROMOSOME 14; CHROMOSOME 2; CHROMOSOME 22; CHROMOSOME 8Q; CLINICAL FEATURE; CLINICAL STUDY; CLINICAL TRIAL; CYTOLOGY; DRUG MEGADOSE; EUROPE; GENE TRANSLOCATION; HUMAN; IMMUNOLOGY; MALE STERILITY; MULTICENTER STUDY; NEUROPROTECTION; NONHODGKIN LYMPHOMA; ONCOGENE C MYC; PALLIATIVE THERAPY; PATIENT CARE; PRIORITY JOURNAL; REVIEW; TIME; TREATMENT OUTCOME; TUMOR CELL; TUMOR LYSIS SYNDROME; ACUTE TOXICITY; CANCER RELAPSE; CANCER STAGING; CHILDHOOD CANCER; CHROMOSOME TRANSLOCATION; DRUG DOSE REGIMEN; DRUG EFFICACY; FOLLICULAR LYMPHOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOBLASTOMA; PROGNOSIS; SOCIAL SUPPORT;

EID: 0036950359     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2002.0231     Document Type: Review

References (60)

1. Hecht JL & Aster JC. Molecular biology of Burkitt's lymphoma. Journal of Clinical Oncology 2000; 18: 3707-3721.
2. Magrath IT. African Burkitt's lymphoma. History, biology, clinical features, and treatment. American Journal of Pediatric Hematology and Oncology 1991; 13: 222-246.
3. Sandlund JT, Downing JR & Crist WM. Non-Hodgkin's lymphoma in childhood. New England Journal of Medicine 1996; 334: 1238-1248.
4. Patte C. Non-Hodgkin's lymphoma. European Journal of Cancer 1998; 34: 359-362.
5. Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Seminars in Oncology 1980; 7: 332-339.
6. Patte C. B-acute lymphoblastic leukaemia. The European experience. International Journal of Pediatric Hemotology/Oncology 1998; 5: 81-88.
7. Pui CH, Mahmoud HH, Wiley JM et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. Journal of Clinical Oncology 2001; 19: 697-704.
8. Patte C, Sakiroglu C, Ansoborlo S et al. Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Societe Francaise d'Oncologie Pediatrique LMB89 protocol. Annals of Oncology 2002; 13: 789-795.
9. Anderson JR, Wilson JF, Jenkin DT et al. Childhood non-Hodgkin's lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). New England Journal of Medicine 1983; 308: 559-565.
10. Patte C, Philip T, Rodary C et al. Improved survival rate in children with stage III and IV B cell non-Hodgkin's lymphoma and leukemia using multi-agent chemotherapy: results of a study of 114 children from the French Pediatric Oncology Society. Journal of Clinical Oncology 1986; 4: 1219-1226.
11. Patte C, Leverger G, Perel Y et al. Updated results of the LMB86 protocol of the French Society of Pediatric Oncology (SFOP) for B-cell non Hodgkin's lymphoma with CNS involvement and B ALL. Medical and Pediatric Oncology 1990; 18: 397 (abstract).
12. Patte C, Philip T, Rodary C et al. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. Journal of Clinical Oncology 1991; 9: 123-132.
13. Philip T, Hartmann O, Biron P et al. High-dose therapy and autologous bone marrow transplantation in partial remission after first-line induction therapy for diffuse non-Hodgkin's lymphoma. Journal of Clinical Oncology 1988; 6: 1118-1124.
14. Gentet JC, Patte C, Quintana E et al. Phase II study of cytarabine and etoposide in children with refractory or relapsed non-Hodgkin's lymphoma: a study of the French Society of Pediatric Oncology. Journal of Clinical Oncology 1990; 8: 661-665.
15. Patte C, Auperin A, Michon J et al. The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001; 917: 3370-3379.
16. Muller-Weihrich S, Beck J, Henze G et al. [BFM study 1981/83 of the treatment of highly malignant non-Hodgkin's lymphoma in children: results of therapy stratified according to histologic immunological type and clinical stage]. Klinic Padiatrics 1984; 196: 135-142.
17. Reiter A, Schrappe M, Parwaresch R et al. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage - a report of the Berlin-Frankfurt-Munster Group. Journal of Clinical Oncology 1995; 13: 359-372.
18. Reiter A, Schrappe M, Tiemann M et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 1999; 94: 3294-3306.
19. Reiter A, Schrappe M, Zimmermann M et al. A 4h infusion of methotrexate 5 g/sqm is not as efficacious for treatment of advanced B-cell neoplasms of chidhood and adolescence than a 24h IV infusion although less toxic. Interim results of trial NHL-BFM 95. Blood 2001; 98: 342a.
20. Atra A, Imeson JD, Hobson R et al. Improved outcome in children with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol. British Journal of Cancer 2000; 82: 1396-1402.
21. Atra A, Gerrard M, Hobson R et al. Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non-Hodgkin's lymphoma (B-NHL) - results of the UKCCSG 9003 protocol. British Journal of Cancer 1998; 77: 2281-2285.
22. Brecher ML, Schwenn MR, Coppes MJ et al. Fractionated cylophosphamide and back to back high dose methotrexate and cytosine arabinoside improves outcome in patients with stage III high grade small noncleaved cell lymphomas (SNCCL): a randomized trial of the Pediatric Oncology Group. Medical and Pediatric Oncology 1997; 29: 526-533.
23. Bowman WP, Shuster JJ, Cook B et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study. Journal of Clinical Oncology 1996; 14: 1252-1261.
24. Schwenn MR, Mahmoud H, Bowman PW et al. Successful treatment of small noncleaved cell lymphoma and B cell ALL with CNS involvement: a Pediatric Oncology Group (POG) study. Journal of Clinical Oncology 2000; 19: abstract no. 2282 (proceedings of the 36th ASCO meeting).
25. Schwenn MR, Mahmoud H, Bowman PW et al. The addition of VP-Ifosfamide did not improve EFS for CNS negative patients with advanced-stage small noncleaved lymphoma or B-cell ALL: a POG study. Journal of Clinical Oncology 2001; 21: abstract no. 1465 (proceedings of the 37th ASCO meeting).
26. Rosanda C, Cantu-Rajnoldi A, Invernizzi R et al. B-cell acute lymphoblastic leukemia (B-ALL): a report of 17 pediatric cases. Haemotologica 1992; 77: 151-155.
27. Cairo MS, Krailo MD, Morse M et al. Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a children's cancer group report. Leukemia 2002; 16: 594-600.
28. Yaniv I, Fischer S, Mor C et al. Improved outcome in childhood B-cell lymphoma with the intensified French LMB protocol. Medical and Pediatric Oncology 2000; 35: 8-12.
29. Kavan P, Kabickova E, Gajdos P et al. Treatment of pediatric B-cell non-Hodgkin's lymphomas at the Motol Hospital in Prague, Czech Republic: results based on the NHL BFM 90 protocols. Pediatric Hematology/Oncology 1999; 16: 201-212.
30. Horibe K, Akiyama Y, Kobayashi M et al. Treatment outcome of AT-B88 regimen for B-cell non-Hodgkin's lymphoma and surface immunoglobulin-positive acute lymphoblastic leukemia in children. International Journal of Hematology 1997; 66: 89-98.
31. Chantada GL, Felice MS, Zubizarreta PA et al. Results of a BFM-based protocol for the treatment of childhood B-non-Hodgkin's lymphoma and B-acute lymphoblastic leukemia in Argentina. Medical and Pediatric Oncology 1997; 28: 333-341.
32. Magrath I, Adde M, Shad A et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. Journal of Clinical Oncology 1996; 14: 925-934.
33. Spreafico F, Massimino M, Luksch R et al. Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children. Journal of Clinical Oncology 2002; 20: 2783-2788.
34. Hesseling PB. High-dose intense chemotherapy in South African children with B-cell lymphoma: morbidity, supportive measures, and outcome. Medical and Pediatric Oncology 2000; 34: 143-146.
35. Hesseling PB. The S.I.O.P. burkitt lymphoma pilot study in Malawi, Africa. Medical and Pediatric Oncology 2000; 34: 142.
36. Burkitt D. Long-term remissions following one and two-dose chemotherapy for African lymphoma. Cancer 1967; 20: 756-759.
37. Djerassi I & Kim JS. Methotrexate and citrovorum factor rescue in the management of childhood lymphosarcoma and reticulum cell sarcoma (non-Hodgkin's lymphomas): prolonged unmaintained remissions. Cancer 1976; 38: 1043-1051.
38. Burkitt D. African lymphoma. Observations on response to vincristine sulphate therapy. Cancer 1966; 19: 1131-1137.
39. Sposto R, Meadows AT, Chilcote RR et al. Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: a report from the Children's Cancer Group. Medical and Pediatric Oncology 2001; 37: 432-441.
40. Magrath I, Adde M, Sandlund J & Jain V. Ifosfamide in the treatment of high-grade recurrent non-Hodgkin's lymphomas. Hematology/Oncology 1991; 9: 267-274.
41. Vassal G, Valteau D, Bonnay M et al. Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with non Hodgkin's lymphoma. Pediatric Hematology/Oncology 1990; 7: 71-77.
42. Morra E, Lazzarino M, Brusamolino E et al. The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia. Clinical results in 46 patients. Cancer 1993; 72: 439-445.
43. Magrath IT, Haddy TB & Adde MA. Treatment of patients with high grade non-Hodgkin's lymphomas and central nervous system involvement: is radiation an essential component of therapy? Leukemia and Lymphoma 1996; 21: 99-105.
44. Haddy TB, Adde MA & Magrath IT. CNS involvement in small non-cleaved-cell lymphoma: is CNS disease per se a poor prognostic sign? Journal of Clinical Oncology 1991; 9: 1973-1982.
45. Sandlund JT, Murphy SB, Santana VM et al. CNS involvement in children with newly diagnosed non-Hodgkin's lymphoma. Journal of Clinical Oncology 2000; 18: 3018-3024.
46. Gururangan S, Sposto R, Cairo MS et al. Outcome of CNS disease at diagnosis in disseminated small noncleaved-cell lymphoma and B-cell leukemia: a Children's Cancer Group study. Journal of Clinical Oncology 2000; 18: 2017-2025.
47. Patte C, Auperin A, Coze C et al. CNS involvement in childhood malignancies: is it a bad prognostic factor per se? Experience of the SFOP LMB89 study. Annals of Oncology 2002; 13 (supplement 2): 147a.
48. Pui CH, Relling MV, Lascombes F et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 1997; 11: 1813-1816.
49. Goldman SC, Holcenberg JS, Finklestein JZ et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001; 97: 2998-3003.
50. Patte C, Laplanche A, Bertozzi AI et al. Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin's lymphoma: a randomized study of the French Society of Pediatric Oncology. Journal of Clinical Oncology 2002; 20: 441-448.
51. Atra A, Gerrard M, Hobson R et al. Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin's lymphoma treated with the UKCCSG 9003/9002 protocols. British Journal of Haematology 2001; 112: 965-968.
52. Ladenstein R, Pearce R, Hartmann O et al. High-dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt's lymphoma: a report from the European Lymphoma Bone Marrow Transplantation Registry. Blood 1997; 90: 2921-2930.
53. Appelbaum FR, Deisseroth AB, Graw RG Jr et al. Prolonged complete remission following high dose chemotherapy of Burkitt's lymphoma in relapse. Cancer 1978; 41: 1059-1063.
54. Hartmann O, Pein F, Beaujean F et al. High-dose polychemotherapy with autologous bone marrow transplantation in children with relapsed lymphomas. Journal of Clinical Oncology 1984; 2: 979-985.
55. Philip T, Hartmann O, Pinkerton R et al. Curability of relapsed childhood B-cell non-Hodgkin's lymphoma after intensive first line therapy: a report from the Societe Francaise d'Oncologie Pediatrique. Blood 1993; 81: 2003-2006.
56. Loiseau HA, Hartmann O, Valteau D et al. High-dose chemotherapy containing busulfan followed by bone marrow transplantation in 24 children with refractory or relapsed non-Hodgkin's lymphoma. Bone Marrow Transplantation 1991; 8: 465-472.
57. Serinet MO, Jacquemin E, Habes D et al. Anti-CD20 monoclonal antibody (rituximab) treatment for Epstein-Barr virus-associated B-cell lymphoproliferative disease in pediatric liver transplant recipients. Journal of Pediatric Gastroenterology and Nutrition 2002; 34: 389-393.
58. Faye A, Quartier P, Reguerre Y et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. British Journal of Haematology 2001; 115: 112-118.
59. Corbacioglu S, Eber S & Niggli F. Successful therapy in a child with relapsed B-ALL with anti CD20 antibodies. European Journal of Pediatrics 2001; 160: (abstract of the annual meeting of the SSP and SSPS.)
60. Veermann A, Nuijens J, van der Schoot C et al. Rituximab in the treatment of childhood B-ALL and Burkitt's lymphoma, report on 3 cases. Blood 1999; 94(10 supplement 1): 269b, abstract of the 41st meeting of the American Society of Hematology.